Considerable debate exists regarding the continuity of bipolar disorder (BD) in children and adolescents. Do affected children continue to have BD as adults? Are pediatric forms of BD distinct from adult forms of the disorder? Here, I argue that, in fact, strictly defined BD I and II in children and adolescents is continuous with adult BD. First, if we take developmental differences into account, children and adults share similar symptoms, since they are both diagnosed according to DSM-IV criteria. Next, retrospective studies indicate that 50% to 66% of adults with BD had onset of their disorder before age 19 years. Early prospective data indicate that adolescents with BD progress to become young adults with BD. Further, family studies of pediatric BD probands find high rates of BD in adult relatives, and pediatric offspring of parents with BD have elevated rates of BD, compared with control subjects. Finally, biological characteristics of pediatric BD (such as treatment response, neurobiology, and genetics) are either shared with adults having BD or fit logically into developmental models of BD. Thus, while not conclusive, a preponderance of data support the hypothesis that pediatric BD is continuous with adult BD. Prospective studies incorporating phenomenological and biological assessment are needed to decisively address this issue. Information on funding and support and author affiliations appears at the end of the article. children suffering from mania may put on plays for the neighbourhood and charge admission. 12 Therefore, if early-onset BD appears far different from adult forms of BD, one could argue that these are 2 different disorders and that a different term should perhaps be used for the pediatric form. 13 This approach makes sense when considering that BD was originally described in adults and not in children and that DSM-IV criteria were developed with adult criteria in mind. 1 This argument may be in some ways impossible to answer until firmer biological markers are established for this disorder and until further understanding of the underlying etiology of BD is achieved. Also, there are linguistic-taxonomic principles that complicate any comparison of the 2 states: What makes a disorder "the same" in 2 different age groups? Is childhood OCD the same as adult OCD, even though children commonly have a different spectrum of symptoms (for example, more obsession with fear of separation) and fewer ego-dystonic characteristics? 14 Similarly, why are children suffering from depression commonly irritable instead of sad, whereas this criterion does not apply to adult depression? Clearly, because children are distinct from adults in their neurodevelopmental and psychosocial stages as well as in their daily environment, one should expect them to have a somewhat distinct presentation of psychiatric disorders. The question therefore becomes: How different can the phenomenological presentation be in children before the same name for the disorder cannot be used?
Further, the cut-off between pediatric and adult BD (typically, age 18 years) is somewhat arbitrary. Biologically, a prepubertal-postpubertal delineation makes more sense. Older adolescent forms of BD often resemble adult forms 15 ; the main discrepancy fuelling the debate is in regard to prepubertal children. However, even early or late adolescents often present with rapid cycling and mixed states that are unlike the clear, first-break, euphoric manic episode that is the hallmark of Kraeplinian BD. Critics have understandably argued that, together with the normal moodiness and experimentation of adolescence, these presentations represent a temporary illness that does not continue into adulthood as true BD. 13 I therefore include discussion of both prepubertal and adolescent forms of BD here, referring to the conglomerate as early-or pediatric-onset BD. Further, unless otherwise specified (for example, as "adolescent"), the term "child" refers to anyone under the age of 18 years.
Another qualifier: for this discussion I concentrate on BD I or II. BD NOS does not currently have any widely agreed-on diagnostic guidelines or firm criteria, and thus there is little research to help understand the causes for the increase in this diagnosis among children in the western hemisphere. 16 Further, I do not consider that children have BD if their manic episodes have only been linked to use of an antidepressant, stimulant, or other exogenous substance. Technically, such children would not meet BD I criteria according to the DSM-IV; the discussion of whether this represents true BD has been conducted elsewhere. 1, 17 Taxonomic roadblocks aside, most researchers and clinicians would typically agree that, if children with BD were followed prospectively into adulthood and still met criteria for BD I or II, this disorder would be the "same" or at least continuous with adult BD. Other cross-sectional measures may also help to compare the 2 forms of BD. For example, Robins and Guze criteria, 18 historically used to identify a distinct psychiatric disorder, could be used to make comparisons between 2 psychiatric conditions. According to these criteria, if 2 disorders share similar symptoms, if one develops into the other longitudinally, if there is familial aggregation of the disorders with each other, and if the 2 disorders share similar biological characteristics (for example, brain biology, genes, or treatment response) then one could argue that they are the same disorder. I will attempt to present just this type of evidence to support the continuity of pediatric BD with adult BD.
Phenomenological Data

Retrospective Data
Most data pertaining to this topic are retrospective, 11, 18 but they strongly support that, most of the time, BD in adults begins in childhood or adolescence. That is, BD I, as strictly defined by structured interviews in adults, begins before age 13 years 15% to 28% of the time and before age 19 years 50% to 66% of the time. 11, 19, 20 The initial presentations, however, are usually depressive symptoms or full depressive episodes, with 20% to 24% of adults having early-onset BD initially presenting with mania. 11 Therefore, prospective data are clearly needed to establish the course of early presentations of full BD.
Longitudinal Data
As mentioned above, it is less clear what type of disorder prepubertal children diagnosed with BD NOS have. First, there are no agreed-on criteria for BD NOS, making rigorous studies of this group difficult. Researchers have classified one type of BD NOS sufferers as those with chronic, nonepisodic, explosive irritability and few other cardinal manic symptoms such as decreased need for sleep, grandiosity, or increased goal-directed activity. 21 These children may have "severe mood dysregulation (SMD)" and, in the community, may be diagnosed with BD NOS. 22 However, longitudinal data suggest that, as adults, these children are more prone to developing recurrent major depression than BD. 23 Similarly, adolescents with BD NOS, loosely defined as meeting DSM-IV mania Criterion A (that is, severe irritability with no other manic symptoms) but not B, also typically do not appear to develop BD I as young adults. 24 However, those with more mania symptoms may be in the developmental stages of full BD I. In a cohort of 92 adolescents with BD NOS (who were defined as having one less Criterion B symptom and a symptom duration of 4 hours, as opposed to 4 to 7 days, with at least 4 cumulative days of such symptoms), 29% of patients developed BD I or II over 22 months, 25 with the highest rates occurring among those with a positive family history of BD (30.6%). 26 What longitudinal data we have of early-onset BD suggest that children with BD I become adolescents with BD I and that adolescents with BD I become young adults with BD I. Geller et al 27 followed 86 patients with prepubertal-onset BD for 4 years, from a beginning mean age of 10.8 years. All subjects continued to meet BD I criteria, with 87.2% recovering from the initial mood episode but 72% relapsing during the 4 years. A similar study, the Course and Outcome of Bipolar Youth study, 23 has shown that children and adolescents with BD (n = 171; mean age at presentation 13.2 years, SD 3.0) continue to suffer from the same disorder 2 years later, with 68% recovering from their index episode but 58% experiencing a recurrence. Thus these children have demonstrated stability of their BD diagnosis through adolescence and, among some, into early adulthood. Clearly, they need to be followed into later adulthood to clarify this argument, which is the intention of both these groups of researchers. Early results, though, do support the continuity of full BD I in childhood with BD I in adulthood.
Familial Aggregation
Recent family studies have indicated about a tenfold risk for BD in relatives of adults with BD, compared with control subjects. 28 Studies using pediatric BD probands have also indicated high rates of BD in adult relatives (for a review, see Althoff et al 29 ). In particular, Strober et al 30 found that early-onset probands had significantly higher rates of BD in relatives than did later-onset probands (29.4% and 7.4%, respectively). Similarly, Neuman et al 31 reported that relatives of early-onset probands with mood disorders were twice as likely to have mood disorders as relatives of later-onset probands. While neither study specified the proportion of adult-onset BD, compared with pediatric-onset BD, in these relatives, most BD reported was likely in adult relatives. Thus pediatric-onset BD not only has a higher familial aggregation of BD than adult-onset BD but this aggregation also extends across pediatric and adult-onset forms, supporting the similarity between the 2 forms.
Cross-sectional studies of pediatric offspring of parents with strictly defined BD I or II have similarly found higher rates of BD than would be normally expected. 32, 33 Many of these offspring first met criteria for ADHD before mania, and a familial, early-onset form of BD that first presents as ADHD and continues into adulthood has been proposed. 34, 35 Although this type of evidence is somewhat circumstantial, it is still supportive of a common process being experienced and expressed in these parents and offspring.
Biological Data
Treatment Response
Treatment response may not a reliable marker when comparing disease states because medications commonly used to treat BD were not originally developed for that purpose. That is, mood stabilizers have wide-ranging properties (for example, antiepileptic, antipsychotic, and anxiolytic, as well as mood stabilizing), such that a positive response is not pathognomonic of BD. However, a drastically different response in one group (for example, in children with worsening mood symptoms after treatment with antipsychotics) might indicate different underlying neurobiology. Then again, because children's brains are dramatically different from adult brains in composition and function, one would not expect psychotropic medications to have similar responses, even in the context of similar disorders.
With the limitations of this approach in mind, it nevertheless generally appears that children and adolescents with BD, while being more treatment-resistant overall, have patterns of response to most mood stabilizers that are similar to those of adults with BD. For example, olanzapine and lithium have been found superior to placebo in treating both children 36, 37 and adults 38, 39 with mania. Conversely, topiramate has been found no different from placebo in treating children 40 or adults with mania, 41 and oxcarbazepine has had similarly negative results in children 42 and has not been yet shown effective in large, placebo-controlled studies in adults. 43 Finally, open and other nonplacebo-controlled studies in pediatric BD suggest that agents such as valproate, 44 risperidone, 45 quetiapine, 46 and lamotrigine 47 have efficacy similar to that found in adults with BD. Thus the overall landscape of treatment response in children with BD appears similar to that in adults with BD.
Neurobiology
Similar neurobiological abnormalities found in both children and adults with BD would further support the continuity of this disorder. Neuroimaging studies in pediatric and adult BD so far implicate prefrontal-limbic structures and circuits in the pathophysiology of BD. 48 Again, it would be simplistic to suggest that specific neurobiological findings in children with BD would be the same for adults, given their vastly different neurodevelopmental states. Rather, findings consistent with an underlying neurodevelopmental hypothesis of BD onset and progression would support the hypothesis of continuity between pediatric and adult forms. For this argument, I will concentrate on areas in which there is a relative abundance of data: the amygdala, the PFC, and the circuits involving these 2 regions.
Amygdala
The amygdala is an excellent candidate for study in BD, owing to its role in mood and emotion regulation. Both adults and children with BD experience relative overactivation of the amygdala when performing emotional tasks. [46] [47] [48] Although this is supportive of neurobiological similarities between the 2, amygdalar overactivation is clearly not specific to BD, having been reported in other conditions, such as anxiety 49, 50 and borderline personality disorder. 51 Regarding morphometry, amygdalar volume in pediatric subjects with BD has been consistently found to be reduced, compared with healthy control subjects. [52] [53] [54] [55] [56] [57] [58] However, adults with BD have been found to have normal, 59 decreased, 52, 59 or even increased 60,61 amygdalar volumes. Thus, at first glance, this incongruity would not support the continuity of BD. However, there may be several explanations for this difference: duration of illness effects, medication effects, or the possibility that a separate pathophysiology exists for children, as opposed to adults, with BD. Regarding medications, we reported that children with BD previously exposed to lithium or valproate tended to have normal amygdalar gray matter volumes, compared with those who did not have such exposure. 57 Therefore, prolonged exposure to mood stabilizers may account for the findings of adults with larger-than-expected amygdalar volumes. Other potential explanations are effects of substance abuse or repeated mood episodes on amygdalar volume. Because the studies in adults cited above did not account for these variables in their analyses, the exact reasons are currently unclear.
Since children with BD usually are temporally closer to their onset of BD and thus have had less time than adults to accrue the influence of external factors, such as medications, substances, or mood episodes, on brain morphometry and function, it is likely that decreased amygdalar volume may be an early trait marker for BD that eventually disappears as a result of these later effects.
Prefrontal Cortex
Similarly, findings in the PFC in pediatric BD may be more representative of true underlying pathophysiology than such findings in adult BD. Adults with BD have been reported to have relatively decreased prefrontal gray matter, including decreased neuronal and glial density in the DLPFC, 62 decreased subgenual prefrontal gray matter 63 and glial cell density, 64 and decreased prefrontal gray matter volumes bilaterally. 65 However, such robust findings of decreased prefrontal volumes have not been detected in children and adolescents with BD. For example, our group found a trend toward decreased cortical gray matter volume in children with BD, 66 but this decrease in cortical gray matter (4.3%) was not as robust as the 9.4% to 16.8 % reported in adults with BD. 65, 67 These morphometric differences are supported by spectroscopic studies. Prefrontal NAA, a marker of neuronal density, was found to be robustly decreased in adults with BD (6.3% on the right, 8.9% on the left), 68 moderately decreased in young adults and older adolescents with BD (6.8% on the left), 69 and only mildly decreased (1.2% on the right, 4.2% on the left) 70 or unchanged, 71 compared with control subjects, in children and adolescents with BD. Mean duration of illness was not established in the study among adults, but it was 3.8 years in the intermediate study and 2.0 years in the negative child study. Further, in the Chang et al spectroscopy study, 70 duration of illness tended to be negatively correlated with the ratio of NAA to creatine (P = 0.065). Thus, rather than revealing neurobiological differences in patients with BD depending on age, these findings suggest that prefrontal neuronal density is fairly intact in childhood BD but gradually decreases with increased duration of illness. Therefore, a likely explanation for the discrepant findings in the PFC between children and adults with BD is that a neurodegenerative process is occurring. Neurodegeneration could be owing to neurotoxic effects of substance use or to repeated mood episodes, 71, 72 or even to exposure to certain medications (although most data point to neuroprotective effects of mediations used to treat BD 73 ). Regardless of etiology, these findings point to a continuity between childhood and adult BD and to the fact that the subjects are the same patients seen at different times in their lives. Functional studies also support this progression. Several studies have reported functional underactivation in the PFC of adults with BD, including the DLPFC, 74 medial PFC, 75 and ventral PFC. 76 Similar studies in children with BD, however, have shown relative overactivation of prefrontal structures. 77, 78 These findings fit the model of abnormal prefrontal-limbic functioning in BD: during early stages of the illness (that is, in childhood), PFC neuronal integrity is largely preserved and overactivated during emotional challenges in attempts to regulate limbic overactivation; however, after prolonged illness and prefrontal neurodegeneration, PFC activation decreases below normal despite continuing limbic hyperactivity. 77 Just as these neurobiological findings support this neurodevelopmental-progressive model of BD, they likewise support the continuity of pediatric with adult BD.
Genes
Although it is clear that BD is a genetically transmitted and mediated disorder, more research is needed in this area to contribute to the current debate on pediatric BD. It appears that there may be many genes that individually confer small increases in risk for BD but, combined with environmental stress, cause the presentation of BD in humans. Some candidate genes (that is, COMT and SERT) linked to cohorts of adults with BD were not found to be associated with pediatric cohorts. 29 So far, however, all pediatric BD genetic studies have suffered from relatively small sample sizes, and so it is not known whether these negative findings are due to low power or to genetic differences between early-and later-onset BD.
Because of the higher genetic aggregation in pediatric BD, it is possible that, while pediatric and adult forms do share common susceptibility genes, separate genes-such as age-at-onset genes-may be responsible for early-onset forms. 79 A good example of this is the case of BDNF. A common functional polymorphism exists for BDNF as a single nucleotide polymorphism at codon 66, resulting in an amino acid change from Val (Val66) to Met (Val66Met). Some association studies have reported association of the Val166 allele with adult BD, 80,81 but others have not been able to replicate this finding. [82] [83] [84] However, linkage disequilibrium of the Val166 allele was reported for a cohort of children with prepubertal-onset BD. 85 Further, Skibinsa et al 86 reported association of BD with the Val66 allele in an early-onset subset of a cohort of adults with BD. Thus it is possible that the Val66 polymorphism preferentially creates risk for early-onset BD. Notably, only recently have most such genetic studies in adults with BD considered age at onset among probands. [86] [87] [88] Thus positive findings for BDNF in earlier adult cohorts might be due to a preponderance of early-onset patients. BDNF, therefore, may or may not be good evidence for shared genetic etiology between the 2 BD forms.
Conclusions
Currently BD I or II appears in up to 4% of adults in the United States, 89 representing an increase of 1% to 2% from previous estimates. 90 This is likely at least partially due to the inclusion of BD II and of irritability as a Criterion A mood for DSM-IV mania. As mentioned above, according to retrospective studies, over 50% of these adults had onset during childhood. Thus, as we broaden the net for describing BD in adults, we need to include the juvenile presentations as being just as "bipolar" as the adult presentations. Further, it is possible that rapid-cycling children with mixed mania do indeed continue to present as rapid-cycling mixed adults-especially since adults with BD do commonly present with atypical features. For example, BD in adults is often chronic and severe (24% of those diagnosed are moderately to severely ill) 91 with mixed states found in 27% of syndromal adults 11 and ultradian cycling in 6.6%. 91 Subthreshold BD that is nevertheless impairing is increasingly being recognized in adults as well 92 and may be present in 5.1% of the US population.
This argument does not hold for children diagnosed with BD NOS. Currently, how to define these children and at what rates they continue on to become adults with BD I or II is not clear. It is also possible that very early forms of mania, such as mania in preschoolers, 93, 94 may not be fully consistent with adult BD. Children with severe early mood, behavioural, and psychotic symptoms likely have abnormal neurodevelopmental trajectories and therefore may have more severe or different outcomes, such as significant symptoms of pervasive development disorder, learning disabilities, and (or) psychosis. 95, 96 Thus the main issue is not whether the BD patient is a child or an adult but at what age and stage of development he or she begins to display impairment due to BD symptoms. A child with BD will likely eventually become an adult with BD-only with a more severe clinical presentation than someone with onset of symptoms at, for example, age 24 years. 11 Although it has been suggested that they are increasingly permeable, 97, 98 the clinical boundaries of BD appear to be appropriate for both adults and children when Robins and Guze criteria are considered. 99 These criteria further suggest that, because both forms of BD share similar symptoms and biological characteristics that fit an underlying neurobiological schema, have high familial aggregation for each other, and appear to be longitudinally consistent, it is likely that, in most cases, pediatric-onset BD is continuous with adult presentations of BD. Ongoing longitudinal phenomenological and neurobiological studies in pediatric BD cohorts will serve to further clarify this discussion. Until then, given the likelihood of continuity between pediatric and adult BD, further efforts to identify and treat or prevent BD in children should no longer be stalled by irrelevant taxonomic arguments. 
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